In 2000, Chinese researchers produced a little over 2% of the world's published physics research in top journals. By 2022, they accounted for more than 23%. In chemistry, the swing was even wider - from under 3% to above 36%. Those are not incremental gains. That is one country rewriting the global map of scientific knowledge in two decades.

A new working paper published by the European Central Bank (ECB) - the institution that sets monetary policy for the eurozone - puts numbers to what many already knew was happening, but now provides something harder to dismiss: causal evidence. The paper does not merely observe that China's research output grew. It shows, with statistical rigor, that a specific government plan launched in 2006 is directly responsible for driving that growth, and that the surge was concentrated in exactly the fields the government chose to target. Everything else - wealth, population size, years of education - was already accounted for in the model.

The implication is simple and uncomfortable for Western policymakers who have long assumed that top-down state planning cannot produce world-class science. It can. It did. And the moment when that assumption was disproved may also be the moment when the United States began cutting its own science budget.

The Background

To understand what happened, it helps to understand what academic research publication actually means economically. A country's presence in top scientific journals is not vanity. It is a leading indicator of future technological and industrial capacity. The discoveries published in Physical Review Letters or The Lancet today become the patents, the treatments, and the technologies that drive productivity growth a decade from now.

For most of modern history, that pipeline ran through Europe and the United States. American universities, funded generously by federal agencies like the National Science Foundation (NSF) and the National Institutes of Health (NIH), produced the bulk of globally influential science. Europe contributed through its national research councils and major universities. China was barely in the picture.

That began to change after 1978, when China started opening its economy and allowed students and scholars to study abroad. Through the 1980s and 1990s, the government encouraged applied research and industrial development, doubled university enrollment, and slowly built the institutional plumbing of a modern research system. But the strategy was still essentially one of catching up - learning from the West, absorbing foreign knowledge, and applying it domestically.

Research and development (R&D) spending refers to the money a country or company invests in creating new knowledge - everything from pharmaceutical trials to particle physics experiments. For most of this period, China's R&D spending as a share of GDP - the total value of everything the country produces - remained modest relative to the US and Europe.

The critical shift came in January 2006. That month, China's State Council published a document that changed the terms of the game entirely. The National Medium- and Long-Term Plan for the Development of Science and Technology - known by its acronym, the NMLP - was not a vague statement of aspiration. It was a directive. It named specific fields. It allocated specific resources. It set a deadline: China would become a global science superpower by 2050.

What Is Actually Happening

The ECB working paper examines more than 300,000 articles published in 40 leading academic journals across six scientific disciplines between 2000 and 2022. The researchers - Catalina Cozariuc, Luc Laeven, and Alexander Popov - then used a statistical technique called difference-in-differences to isolate the NMLP's specific effect. The method works by comparing fields the government explicitly targeted - physics, chemistry, biology, and medicine - against fields it did not: mathematics and economics.

The logic is clean. If China's overall rise simply reflected wealth or a bigger population, it should have appeared equally across all fields. It did not. The gap between targeted and non-targeted fields is where the plan's fingerprints appear.

The results are stark. After 2006, publications per million population by China-based researchers rose by roughly 17% above the global trend. Citations - a measure of research influence, tracking how often a paper is referenced by other scientists - rose by 140%. But inside the targeted fields, the effect was much larger. Publication output in physics, chemistry, biology, and medicine rose by around 26% relative to the non-targeted comparison group. By 2022, the gap had widened to 85%.

In chemistry, China's share of top-journal publications went from under 3% in the early 2000s to over 36% by the period 2017-2022. In physics, from 2% to 23%. Meanwhile, in economics - a field deliberately not prioritized, and one whose critical orientation toward policy may have made it politically sensitive - China's share barely moved, staying below 2% even by 2022. The US, by contrast, still controls over 63% of economics research in top journals.

Nature reported that China overtook the United States as the top contributor to the Nature Index - a ranking of high-quality natural science research - for the first time in 2022. The National Science Foundation's own data, cited in the ECB paper, confirms that China had become the world's largest overall producer of scientific publications by that year, with 27% of global output compared to the US's 14%.

What makes the ECB analysis notable is not the trend, which was already documented, but the mechanism. The paper checks whether the effect could be explained by simply funding more researchers, by changes in government grants, or by spillover effects from targeted fields bleeding into untargeted ones. None of those alternative explanations hold. The effect disappears in non-targeted fields. It is concentrated where the state pointed its money.

The Money Trail

The NMLP was not cheap. China's R&D spending nearly doubled in the years immediately following the plan's launch. By 2020, according to the ECB paper, total R&D expenditure had reached the equivalent of roughly $378 billion per year, representing 2.4% of GDP. That is close to what the US spent on R&D as a share of its economy. For a country that was still building its research infrastructure from a relatively low base, that rate of spending growth was extraordinary.

The money was not spread evenly. The plan explicitly targeted four areas - biotechnology and life sciences, quantum electronics and computing, nanotechnology, and reproductive biology. These were fields identified as having both scientific frontier potential and strategic industrial relevance. The logic was explicitly economic: science as a tool of industrial upgrading, the process by which a country moves its economy from low-value manufacturing into high-value, knowledge-intensive production.

The ECB paper makes an important point about who benefited and who did not. The gains were not distributed across Chinese society. They were concentrated in specific research institutions - universities and laboratories receiving direct government funding. The National Natural Science Foundation of China alone funded 8.7% of all articles in the study's dataset. That is a lot of directed money flowing through a narrow set of channels.

For the United States and Europe, the math runs in the opposite direction. The US started from a dominant position - holding 46-52% of biology publications in top journals in the early 2000s, and over 76% of economics research. That lead has eroded sharply in the natural sciences. The ECB paper finds that China's rise in publications came "mostly at the expense of the United States," which held a larger initial share than Europe. For citations - the quality measure - the impact on European research institutions was comparatively stronger.

The competitive pressure this creates is not abstract. Scientific leadership has direct economic consequences. Countries with strong research systems attract more skilled workers, generate more patents, develop more commercially valuable technologies, and can set international standards in emerging industries. China's targeted investment in physics, chemistry, and materials science maps closely onto the industries it has since come to dominate: semiconductors, batteries, solar panels.

There is also a field that conspicuously did not benefit from state investment: economics. The paper notes that economics and mathematics showed "significantly less growth" under the plan, and suggests this may reflect political and institutional constraints - critical social science analysis of policy and institutions does not always sit comfortably inside a centrally planned research funding system. China's dominance in STEM has not translated into comparable influence in the discipline that analyzes how markets, governments, and incentives actually work.

What People Are Doing About It

The response in the United States has been incoherent, oscillating between restrictions on Chinese scientific access and cuts to domestic research funding that weaken the very base the restrictions were designed to protect.

The Biden administration's 2022 CHIPS and Science Act explicitly limited research cooperation with China in semiconductors and some advanced technologies. The Trump administration followed with tariffs and export controls targeting Chinese access to advanced chips and equipment. Research by American Physical Society found that as of 2026, NSF has awarded just 613 grants this fiscal year - roughly 20% of the level seen in each of the prior four years.

The picture on domestic funding is more complicated. The Trump administration proposed dramatic cuts: the Brennan Center for Justice documented a request to reduce NSF by 57%, NIH by 41%, and NASA by 24% in fiscal year 2026. Congress largely blocked those cuts, holding funding broadly stable for 2026. But the FY2027 budget proposes a 54.5% cut to NSF - down from $8.8 billion to $4 billion. Funding for mathematical and physical sciences at NSF would drop from $1.56 billion in 2025 to $515 million. Biological sciences funding would fall from $801 million to $225 million.

Even where Congress has held firm, the disruption has had effects. More than 25,000 people left US science agencies in 2025, many at early-career stages. International doctoral student applications to US universities fell by roughly 5%. Uncertainty about future funding has slowed grant approvals and, according to the Brennan Center, reduced support for new areas of inquiry, as agencies quietly prioritized paying off existing multi-year commitments over making new ones.

In Europe, the response has been more directed but not dramatically better funded. The EU's Horizon research program increased its budget in the current cycle, and several member states have announced science investment plans. But no European government has matched the scale or strategic coherence of China's sustained 20-year investment.

China, meanwhile, continues. Its 14th Five Year Plan (2021-2025) raised the target for basic research - the kind of foundational science with no immediate commercial application - to at least 8% of total R&D funding, a recognition that earlier investment had been weighted toward applied work. The 15th Five Year Plan, covering 2026-2030, is expected to sustain or increase those commitments.

The Bottom Line

A large-scale natural experiment in government science policy just concluded, and the ECB has published the results. China picked specific scientific fields, directed sustained public money into them for nearly two decades, and produced measurably more and higher-impact research than comparable countries - regardless of wealth, population, or education levels. The gap is not narrowing. In targeted fields, Chinese publication output was 85% higher than the control group by 2022. The fields China did not target barely moved. The mechanism was the policy. That is not the outcome Western economic orthodoxy predicted, and the countries that built their research systems on the assumption that central planning cannot produce frontier science may need to revise more than just their research budgets.

Timeline

  • 1978 - China begins opening its economy; allows students and scholars to study abroad
  • 1985 - China passes resolution to strengthen applied research over fundamental research
  • 1989 - Student protests lead to temporary break with Western institutions; STEM favored over humanities and social sciences
  • 2000-2005 - China-based researchers account for 2.1% of physics publications and 2.4% of chemistry publications in top journals
  • January 2006 - China launches the National Medium- and Long-Term Plan for the Development of Science and Technology (NMLP), targeting physics, chemistry, biology, and medicine
  • 2006 - China overtakes Japan and the UK to become the world's second-largest producer of scientific papers, according to EU research records
  • 2010 - China's R&D spending has nearly doubled since the NMLP launch
  • 2013 - Xi Jinping becomes president; science and innovation policy made central to development strategy; China overtakes Japan as world's second-largest R&D spender
  • 2015 - Tu Youyou becomes China's first China-based Nobel laureate in the natural sciences
  • 2016-2020 - China's 13th Five Year Plan sets innovation-driven development as its central strategy
  • 2020 - China's total R&D spending reaches approximately $378 billion per year, or 2.4% of GDP
  • 2021-2025 - China's 14th Five Year Plan raises basic research target to at least 8% of total R&D funding
  • 2022 - China overtakes the US as the top contributor to the Nature Index for high-quality natural science research; China holds 27% of global scientific output vs. the US's 14%
  • 2022 - China's chemistry share of top-journal publications reaches 36.4%; physics reaches 23.5%
  • 2022 - US passes CHIPS and Science Act, restricting research cooperation with China in semiconductors
  • 2025 - Trump administration cuts or freezes over $3 billion in previously approved NIH and NSF research grants; more than 25,000 people exit US science agencies
  • February 2026 - Congress blocks deepest proposed US science funding cuts, holding 2026 budgets broadly stable; NSF takes a 3.4% cut
  • April 2026 - Trump FY2027 budget proposes 54.5% cut to NSF, down to $4 billion; NSF issues just 613 grants in 2026, roughly 20% of normal volume
  • May 2026 - ECB working paper published, establishing causal link between China's 2006 NMLP and 26% rise in targeted research output

Summary

Who: China, the United States, the European Union, and the researchers documented in a new European Central Bank working paper

What: An ECB study of more than 300,000 articles published between 2000 and 2022 finds that China's 2006 National Medium- and Long-Term Plan for Science and Technology directly caused a 26% increase in research output in targeted fields, and an 85% output gap versus non-targeted fields by 2022 - propelling China past the US as the world's leading producer of scientific research in natural sciences

When: The NMLP was launched in January 2006; its effects were measurable within a few years and widened consistently through 2022; the ECB paper was published in May 2026

Where: The shift is most visible in chemistry, physics, biology, and medicine - fields explicitly targeted by the Chinese state; it is absent in economics and mathematics, which were not prioritized

Why: China invested in science as a tool of industrial and geopolitical strategy; the ECB paper shows the investment worked, challenging the long-standing assumption that centralized, state-directed research systems cannot produce frontier innovation - a finding that arrives precisely as the United States is moving in the opposite direction on science funding